449 results on '"Jasani, Bharat"'
Search Results
2. Global Ring Study to Investigate the Comparability of Total Assay Performance of Commercial Claudin 18 Antibodies for Evaluation in Gastric Cancer
3. Comparison of HercepTest™ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status
4. High Interobserver Variability Among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma
5. AI in the Post-Analytical Phase
6. Description and Interpretation of Results; The Pathology Report
7. Introduction to Digital and Computational Pathology
8. AI in the Analytical Phase
9. AI in the Decision Phase
10. Role of Pathologist in Precision Molecular and Digital Image Analyses
11. The Practical Challenges for Pathology: Multiple Rapidly Evolving Methods
12. Role of Pathologist in Precision Cancer Diagnosis
13. Introduction: From ‘Tissue Diagnosis’ to Biomarkers
14. Implementation of Precision Cancer Diagnostic Test
15. Analytical Phase: Protocol and Antigen Retrieval
16. Pre-Analytic Phase: Test Selection; Specimen Acquisition and Handling
17. Analytical Phase: Principles for Immunohistochemistry (IHC)
18. Analytical Phase: Current Controls; Fit for Purpose Selection and Validation
19. Evolution of the Total Test Approach to Tissue Based Pathological Analysis
20. Analytical Phase: Alternative and New Control Systems
21. Post-Analytic Phase: Interpretation, Scoring and Reporting of Biopsy Results
22. Pre-Analytical Phase: Biopsy/Tissue Handling and Processing
23. The Advent of Biomarker Testing
24. Pre-Analytic Phase: Specimen Type and Acquisition
25. Immunofluorescence, In Situ Hybridization and Alternative Forms of ‘Labeled’ Microscopy
26. In Support of Magnani and Taylor
27. ISH-based HER2 diagnostics
28. Quality Control of Immunohistochemical and In Situ Hybridization Predictive Biomarkers for Patient Treatment: Experience from International Guidelines and International Quality Control Schemes
29. Predictive Biomarkers and Targeted Therapies in Colorectal Cancer
30. Tumor cell cytoplasmic metallothionein expression associates with differential tumor immunogenicity and prognostic outcome in high-grade serous ovarian carcinoma
31. Global ring study to investigate the comparability of total assay performance of commercial claudin 18 antibodies for evaluation in gastric cancer
32. ISH-basierte HER2-Diagnostik
33. Precision Cancer Medicine
34. Optimization and validation of PD-L1 immunohistochemistry staining protocols using the antibody clone 28-8 on different staining platforms
35. Impact of Analytical Variables in Breast Cancer Biomarker Analysis
36. Evaluation of an online training tool for scoring programmed cell death ligand-1 (PD-L1) diagnostic tests for lung cancer
37. Does Simian Virus 40 (SV40) Have a Role in UK Malignant Pleural Mesothelioma? No Role is Identified in a Sensitive RNA In Situ Hybridization Study on Potentially Affected Birth Cohorts
38. Quality Control of Immunohistochemical and In Situ Hybridization Predictive Biomarkers for Patient Treatment: Experience from International Guidelines and International Quality Control Schemes
39. Predictive Biomarkers and Targeted Therapies in Colorectal Cancer
40. Supplementary Figure 2 from Somatic Profiling of the Epidermal Growth Factor Receptor Pathway in Tumors from Patients with Advanced Colorectal Cancer Treated with Chemotherapy ± Cetuximab
41. Supplementary Figure 3 from Somatic Profiling of the Epidermal Growth Factor Receptor Pathway in Tumors from Patients with Advanced Colorectal Cancer Treated with Chemotherapy ± Cetuximab
42. Supplementary Figure Legends from Somatic Profiling of the Epidermal Growth Factor Receptor Pathway in Tumors from Patients with Advanced Colorectal Cancer Treated with Chemotherapy ± Cetuximab
43. Supplementary Figure 1 from Somatic Profiling of the Epidermal Growth Factor Receptor Pathway in Tumors from Patients with Advanced Colorectal Cancer Treated with Chemotherapy ± Cetuximab
44. Supplementary Materials and Methods and Tables 1-5 from Somatic Profiling of the Epidermal Growth Factor Receptor Pathway in Tumors from Patients with Advanced Colorectal Cancer Treated with Chemotherapy ± Cetuximab
45. Erratum to High Interobserver Variability Among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma [Modern Pathology 36(5) (2023) 100154]
46. Impact of updated HER2 testing guidelines in breast cancer—re-evaluation of HERA trial fluorescence in situ hybridization data
47. FOCUS4 biomarker laboratories: from the benefits to the practical and logistical issues faced during 6 years of centralised testing.
48. The PD-1/PD-L1 Pathway: A Perspective on Comparative Immuno-Oncology
49. High interobserver and intraobserver reproducibility among pathologists assessing PD‐L1 CPS across multiple indications
50. Interlaboratory concordance of PD‐L1 immunohistochemistry for non‐small‐cell lung cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.